Asthma Symptoms Alone Offer Limited Insight into Attack Risk

ASTHMA SYMPTOM scores offered only modest information about future severe attacks and did not reliably identify response to anti-inflammatory treatment in a patient-level analysis.

The findings suggest that how a patient feels and what is happening within their airways may provide different information. Symptoms remain central to care, but may need to be interpreted alongside objective measurements when considering treatment escalation.

Assessing Symptoms Across Studies

Researchers examined five datasets encompassing 7,161 participants with asthma of varying severity. The main analysis used control-group data from 22 randomised trials.

Symptom burden was measured with the five-item Asthma Control Questionnaire, known as ACQ-5. Higher baseline scores were associated with a modest increase in future attack risk.

However, symptom scores did not consistently align with other clinical, physiological or inflammatory features. They also did not identify differences in the attack-prevention benefit of intravenous mepolizumab in the DREAM trial.

Biomarkers Added Information

Blood eosinophil counts and fractional exhaled nitric oxide, or FeNO, more reliably identified anti-inflammatory treatment response. Patients with high levels of both showed particularly substantial benefit from mepolizumab in the analysis.

Eosinophils are immune cells that can be involved in airway inflammation. FeNO testing measures nitric oxide in exhaled breath, with higher values potentially indicating inflammation.

These measurements provide information that is different from a symptom questionnaire. They do not replace the patient’s account, but can help clarify the biological context in which symptoms occur.

Understanding the Clinical Context

Asthma assessment already draws on several sources of information. Spirometry measures the amount and speed of exhaled air, while bronchodilator testing assesses how breathing changes after a medicine that opens the airways.

Together with history and other tests, these measurements help clinicians build a fuller picture than any single result can provide.

The new findings strengthen the case for distinguishing symptom relief from prevention of severe attacks. A treatment decision intended to improve daily comfort may not involve exactly the same considerations as one intended to reduce inflammation-related attack risk.

Implications for Treatment Decisions

The analysis does not suggest ignoring breathlessness, wheeze or other troubling symptoms. Instead, it raises questions about using symptom scores alone to decide that stronger anti-inflammatory treatment is needed.

The practical implication is to interpret symptom burden in context, alongside inflammatory markers and other relevant clinical findings.

Because the evidence combines selected trial populations with additional observational datasets, its application requires consideration of the patient and treatment being assessed. The study supports a more complete assessment of asthma, rather than a single biomarker threshold or an automatic rule for prescribing biologics.

Reference

Couillard S et al. Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies. Lancet Respir Med. 2026;14(10):869-882.